bi 1291583
Small moleculeexperimental
Clinical trial activity
16 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 5, 2018 (NCT03414008)
Timeline
Indications
Mechanism of action
- Dipeptidyl peptidase IINHIBITOR
CTSC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07023354 | Phase 1 | Jul 17, 2025 | Boehringer Ingelheim |
| NCT06872892 | Phase 3 | Jun 16, 2025 | Boehringer Ingelheim |
| NCT06917872 | Phase 1 | Apr 29, 2025 | Boehringer Ingelheim |
| NCT06791187 | Phase 1 | Jan 23, 2025 | Boehringer Ingelheim |
| NCT06631417 | Phase 1 | Oct 21, 2024 | Boehringer Ingelheim |
| NCT05865886 | Phase 2 | Jan 31, 2024 | Boehringer Ingelheim |
| NCT06166992 | Phase 1 | Dec 12, 2023 | Boehringer Ingelheim |
| NCT05846230 | Phase 2 | Jul 21, 2023 | Boehringer Ingelheim |
| NCT05833035 | Phase 1 | Apr 24, 2023 | Boehringer Ingelheim |
| NCT05238675 | Phase 2 | Mar 21, 2022 | Boehringer Ingelheim |
| NCT05183347 | Phase 1 | Feb 4, 2022 | Boehringer Ingelheim |
| NCT04866160 | Phase 1 | May 17, 2021 | Boehringer Ingelheim |
| NCT03890887 | Phase 1 | Apr 12, 2019 | Boehringer Ingelheim |
| NCT03868540 | Phase 1 | Mar 28, 2019 | Boehringer Ingelheim |
| NCT03837964 | Phase 1 | Feb 27, 2019 | Boehringer Ingelheim |
| NCT03414008 | Phase 1 | Feb 5, 2018 | Boehringer Ingelheim |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 16 | 16 | 3 | 2018 |
1 organizations
Page 1 / 1